Beyond 2030. The future of life sciences
| Tag | 1 | 2 | Valor |
|---|---|---|---|
| LDR | 00000cam a22000004 44500 | ||
| 001 | MAP20260051062 | ||
| 003 | MAP | ||
| 005 | 20261009094200.0 | ||
| 008 | 261007s2026 che|||| ||| ||eng d | ||
| 040 | $bspa$aMAP$dMAP | ||
| 084 | $a931 | ||
| 245 | 1 | 0 | $aBeyond 2030. The future of life sciences |
| 260 | $a[Zurich]$bZurich Insurance Group$c2026 | ||
| 300 | $a34 p. | ||
| 505 | 0 | $aForeword -- Key findings -- What changes in practice -- Where the next opportunity lies -- 1. The New Health Cold War: Who controls the means of making medicine? -- 2. The Innovation Stack: Who turns discovery into scale? -- 3. The Self-Directed Patient: Who is responsible for care beyond care? -- 4. The Cost of Cure: Who can afford the breakthrough? -- Data and methodology -- Acknowledgments | |
| 520 | $aThis sector foresight report analyzes how life sciences will evolve beyond 2030, arguing that success will depend less on scientific breakthroughs and more on what happens after them: generating proof, manufacturing at scale, navigating policy and regulation, securing digital and physical bottlenecks, and financing outcomes. It highlights four shiftsproof as bottleneck, national security shaping innovation, care moving beyond institutions, and curative models disrupting revenueand outlines strategic priorities: anticipating constraints early, securing critical dependencies, and building accountability into product design. The report examines AI's accelerating role, geopolitical and supply-chain choke points, cyber risks, personalized medicine, evolving regulatory/liability frameworks, and the economics of one-time or outcome-based therapies. It concludes that advantage will rest on resilience, evidence, trust, and long-term stewardship across interconnected systems of technology, regulation, delivery, and finance. | ||
| 522 | $aInternacional | ||
| 650 | 4 | $0MAPA20080539771$aSalud | |
| 650 | $0MAPA20080611200$aInteligencia artificial | ||
| 650 | $0MAPA20080606633$aIndustria farmacéutica | ||
| 650 | $0MAPA20080567262$aSalud pública | ||
| 650 | $0MAPA20250003316$aGestión de riesgos | ||
| 650 | 4 | $0MAPA20250003248$aSistemas de salud | |
| 650 | 4 | $0MAPA20080545314$aSanidad | |
| 710 | $0MAPA20130000626$aZurich Insurance Group | ||
| 787 | 0 | $wMAP20260037714$aZurich Insurance Group$tBeyond 2030: The future of construction$dZurich : Zurich Insurance Group, 2026 | |
| 856 | $uhttps://www.zurich.com/insights/business/the-future-of-life-sciences |